PD-1/PD-L1 inhibitors have shown promising activity in the first clinical trials in breast cancer, and some trials are testing their efficacy and safety in the metastatic and neoadjuvant setting [43, 45, 46]. This evidence concerns the gene PDCD1 and breast carcinoma.